Immunome Inc at Goldman Sachs Healthcare Conference Transcript
Great, good morning, everyone. Thank you for joining us. It's my pleasure to introduce Immune Oman, and with us we have Max Rosette, CFO of the company.
Questions & Answers
Max, to start here, thank you for joining us. Immunome is a targeted oncology company developing third-generation ADCs. At the same time, you have a commercial asset that's headed to launch here. Can you give us a high-level overview of the company and where your programs stand and what updates we can anticipate in the second half or over the next 12 to 18 months?
Of course. Thank you for having me here. It's a pleasure to be here. As you said. Immunome is a targeted oncology company, and there really are two pillars to this story. We view varagasis step, our gamma secretase inhibitor for which we recently submitted an NDA as. Fantastic asset. We're really excited to be preparing to launch that over the remainder of this year. That launch preparation, I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
